News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
Tom Lee的Bitmine再次质押159,728枚以太坊
BiJie Network data: According to Cointelegraph, Tom Lee's Bitmine has once again staked 159,728 ETH, worth approximately $390.6 million, bringing its total staked amount to 5.23 million ETH, accounting for 86.5% of its holdings.
Peter Brandt predicts Bitcoin will reach $500,000 this cycle.
CoinWorld news: Investment legend Peter Brandt predicts that Bitcoin will reach $500,000 in this cycle, and expects it to reach $300,000 before the halving, with the cycle lasting until the end of 2029.
The long-to-short account ratio for ETH contracts is 2.74.
CoinWorld data: The ETHUSDT 4-hour long-short account ratio is 2.74, with more net long accounts than net short accounts. Compared with the same-caliber snapshot 24 hours ago, it is down 0.3016; compared with the same-caliber snapshot 7 days ago, it is up 0.0765.
Shinhan Bank and KSNET complete proof-of-concept for stablecoin-based medical expense settlement
On October 21, CoinWorld news reported that Shinhan Bank, together with ksnet, completed a proof-of-concept test in which foreign patients paid medical fees using stablecoins while Korean medical institutions received payment in Korean won. The test was conducted at a medical institution in Seoul. The process involved a foreign patient paying with stablecoins, an overseas regulated institution converting them into fiat currency and remitting the funds to Korea, and ksnet paying the medical institution in Korean won. Shinhan Bank verified the feasibility of linking the financial infrastructure required for domestic collection and Korean won settlement.
Analyst: The digital renminbi infrastructure service system has been comprehensively upgraded.
CoinWorld news: On October 21, the Digital RMB Operations Management Center publicly announced the digital RMB infrastructure service system, unveiling two core achievements: the central bank-side digital RMB system (dceps) and the digital RMB smart contract ecosystem service framework (e-cny smart contract).
During Trump's second term, the U.S. has revoked more than 300,000 visas.
According to CoinWorld news, during Trump's second term, U.S. State Department spokesperson Tommy Pigott stated that the United States has revoked more than 300,000 visas. He noted that the Trump administration has surpassed all previous U.S. administrations in both the number and speed of visa revocations, and has adopted a zero-tolerance attitude toward visa holders who break the law, commit fraud, or endanger national security in the United States.
A whale holding 80,000 ETH has an unrealized profit of $30.79 million and appears to be selling 75.03 WBTC and KBTC.
According to data from Bijie.com: a certain whale holds 80,000 ETH, with unrealized gains of approximately $30.79 million, and has not yet reduced its position. Four hours ago, the whale appeared to sell 75.03 WBTC and KBTC, worth about $6.2 million; the average withdrawal price of the related tokens was $78,069, and if sold, it would realize a profit of $346,000.
Bithumb将上线PYBOBO
According to a CoinWorld report, Bithumb has announced in an official notice that it will list the PYBOBO trading pair.